甲磺酸阿帕替尼与替吉奥治疗晚期胃癌的疗效和安全性比较

Comparison of efficacy and safety of apatinib mesylate versus tegafur for advanced gastric cancer

目的探讨甲磺酸阿帕替尼与替吉奥在晚期胃癌患者中的治疗效果与安全性的比较。方法选取2016年1月至2017年6月间安徽省砀山县人民医院收治的64例晚期胃癌患者进行回顾性分析,采用口服甲磺酸阿帕替尼治疗的32例患者纳入观察组,采用口服替吉奥治疗的32例患者纳入对照组。比较两组患者治疗4周后的疾病控制率及不良反应发生率。结果两组患者近期疗效比较,差异无统计学意义(P>0.05)。服用甲磺酸阿帕替尼和替吉奥的不良反应主要有腹泻、白细胞减少、手足综合征及高血压,观察组患者不良反应发生率为34.4%,低于对照组患者的56.3%,差异有统计学意义(P<0.05)。结论甲磺酸阿帕替尼用于治疗晚期胃癌疗效确切,能够降低不良反应的发生率。

Objective To investigate the efficacy and safety of apatinib mesylate versus tegafur in patients with advanced gastric cancer. Methods A total of 64 patients with advanced gastric cancer treated at Dangshan County People＇s Hospital from January 2016 to June 2017 were retrospectively analyzed. Thirtytwo patients who were given oral apatinib mesylate were involved in the observation group and 32 patients who were given oral tegafur were involved in the control group. After four weeks of treatment,the disease control rate and the incidence of adverse reactions were observed and recorded between the two groups.Results There was no significant difference in short-term efficacy between the two groups（ P〉0. 05）. The adverse reactions for apatinib mesylate and teglio mainly were diarrhea,leukopenia,hand-foot syndrome,and hypertension. The incidence of adverse reactions was 34. 4% for the observation group,which was significantly lower than 56. 3% of the control group（ P〈0. 05）. Conclusion Apatinib mesylate is effective in the treatment of advanced gastric cancer,which can significantly reduce the incidence of adverse reactions in patients with advanced gastric cancer.